Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Neurofibromatosis type 1 (NF1) is one of the most common genetic disorders causing learning disabilities by mutations in the neurofibromin gene, an important inhibitor of the RAS pathway. In a mouse model of NF1, a loss of function mutation of the neurofibromin gene resulted in increased gamma aminobutyric acid (GABA)-mediated inhibition which led to decreased synaptic plasticity and deficits in attentional performance. Most importantly, these defictis were normalized by lovastatin. This placebo-controlled, double blind, randomized study aimed to investigate synaptic plasticity and cognition in humans with NF1 and tried to answer the question whether potential deficits may be rescued by lovastatin. Methods: In NF1 patients (n = 11; 19–44 years) and healthy controls (HC; n = 11; 19–31 years) paired pulse transcranial magnetic stimulation (TMS) was used to study intracortical inhibition (paired pulse) and synaptic plasticity (paired associative stimulation). On behavioural level the Test of Attentional Performance (TAP) was used. To study the effect of 200 mg lovastatin for 4 days on all these parameters, a placebo-controlled, double blind, randomized trial was performed. Results: In patients with NF1, lovastatin revealed significant decrease of intracortical inhibition, significant increase of synaptic plasticity as well as significant increase of phasic alertness. Compared to HC, patients with NF1 exposed increased intracortical inhibition, impaired synaptic plasticity and deficits in phasic alertness. Conclusions: This study demonstrates, for the first time, a link between a pathological RAS pathway activity, intracortical inhibition and impaired synaptic plasticity and its rescue by lovastatin in humans. Our findings revealed mechanisms of attention disorders in humans with NF1 and support the idea of a potential clinical benefit of lovastatin as a therapeutic option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367
Rossini, P. M., Barker, A. T., Berardelli, A., Caramia, M. D., Caruso, G., Cracco, R. Q., Dimitrijević, M. R., Hallett, M., Katayama, Y., Lücking, C. H., et al. (1994) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(94)90029-9 · Cited by 3,030 · cited 1×
“MEP size was determined by measuring the two highest peaks of opposite polarity [29,39,40] and then averaged over 20 trials for each point of investigation.”
MethodEarly consolidation in human primary motor cortex
Muellbacher, W., Ziemann, U., Wissel, J., Dang, N., Kofler, M., Facchini, S., Boroojerdi, B., Poewe, W., & Hallett, M. (2002) · Nature · doi:10.1038/nature712 · Cited by 803 · cited 1×
“MEP size was determined by measuring the two highest peaks of opposite polarity [29,39,40] and then averaged over 20 trials for each point of investigation.”
MethodDeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., & Lowy, D. R. (1992) · Cell · doi:10.1016/0092-8674(92)90407-4 · Cited by 580 · cited 1×
“It is caused by a loss of function mutation of the neurofibromin gene leading to rat sarcoma (RAS) pathway hyperactivity [1,2].”
BackgroundModifying motor learning through gating and homeostatic metaplasticity
Ziemann, U., & Siebner, H. R. (2008) · Brain Stimulation · doi:10.1016/j.brs.2007.08.003 · Cited by 269 · cited 1×
“These findings lead to the concept of a balance between gating and anti-gating of synaptic plasticity which is regulated by intracortical inhibition [30] and which may conclusively explain our results.”
ResultCortical Plasticity in Alzheimer’s Disease in Humans and Rodents
Battaglia, F., Wang, H.-Y., Ghilardi, M. F., Gashi, E., Quartarone, A., Friedman, E., & Nixon, R. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.027 · Cited by 175 · cited 1×
“Impaired LTP-like plasticity, has also been described in neuropsychiatric conditions such as Alzheimer’s disease [24], in patients with schizophrenia [25] as well as in patients with Parkinson’s disease [26,27].”
Background
Cited by
Cerebral plasticity: windows of opportunity in the developing brain
Ismail, F. Y., Fatemi, A., & Johnston, M. V. (2017) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2016.07.007 · Cited by 572
Dendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464
SHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232
Metadata
- Authors
- Mainberger, F., Jung, N. H., Zenker, M., Wahlländer, U., Freudenberg, L., Langer, S., Berweck, S., Winkler, T., Straube, A., Heinen, F., Granström, S., Mautner, V.-F., Lidzba, K., & Mall, V.
- Venue
- BMC Neurology
- Published
- 2013-10-02
- Volume
- 13
- Issue
- 1
- Pages
- 131-131
- ISSN
- 1471-2377 (ISSN-L)
- OpenAlex
- W2041371410
- Cited by
- 86
- References
- 6
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1. https://app.cochat.ai/papers/10.1186/1471-2377-13-131
- The paper
- Mainberger, F., Jung, N. H., Zenker, M., Wahlländer, U., Freudenberg, L., Langer, S., Berweck, S., Winkler, T., Straube, A., Heinen, F., Granström, S., Mautner, V.-F., Lidzba, K., & Mall, V. (2013). Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1. BMC Neurology. https://doi.org/10.1186/1471-2377-13-131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.